Fierce Pharma
APRIL 15, 2024
A Novartis drug with "pipeline in a pill" potential, according to one analyst group, has delivered on that promise once again. | In a phase 3 trial, treatment with Fabhalta led to a statistically significant 38.3% reduction of proteinuria (protein in the urine) in patients with IgA nephropathy, Novartis said on Monday.
MedCity News
APRIL 15, 2024
Two CVS stores in Rhode Island have filed petitions to join the Pharmacy Guild, which is building a national pharmacy union. The locations are close to CVS Health’s headquarters in Woonsocket, Rhode Island. The post Two CVS Locations Make Moves To Join National Pharmacy Union Movement appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 15, 2024
After nearly two years of legal back and forth, Pfizer and its German partner BioNTech have won a brief reprieve in their patent fight against mRNA rival Moderna. | In a docket entry dated Friday, Massachusetts federal judge Richard G. Stearns granted a stay on Moderna's COVID-19 vaccine patent infringement lawsuit against Pfizer and BioNTech. The move will give the Patent Trial and Appeal Board more time to review challenges against two of the three relevant patents in the litigation.
PharmaVoice
APRIL 15, 2024
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
APRIL 15, 2024
Boehringer Ingelheim’s 2023 was largely marked by the highly anticipated launch of its Cyltezo, the first interchangeable biosimilar to AbbVie’s Humira. | The company's late-stage pipeline focuses on oncology, cardiorespiratory diseases, mental health and cardiovascular-renal-metabolic conditions. Boehringer looks to kick off ten new phase 2 and 3 trials in the next 12-18 months, it said in its earnings release.
Eversana Intouch
APRIL 15, 2024
At SXSW 2024, amidst a confluence of marketing, technology, AI, and design, one word seemed to echo through every conversation, panel, and workshop: authenticity. It’s fascinating, isn’t it? The idea of being genuine, real, and true — qualities so deeply sought after in everything we do, yet so complex and rich when we pause to unpack them. Among the minds at EVERSANA INTOUCH, with leaders spanning the spectrum from Strategic Planning to Creative Direction, and from Experience Design to Customer
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
APRIL 15, 2024
Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.
Fierce Pharma
APRIL 15, 2024
Marinus Pharmaceuticals’ attempt to expand the use of its seizure medicine in a new formulation has hit a pothole. | Marinus Pharmaceuticals’ attempt to expand the use of its seizure medicine in a new formulation has hit a pothole. As a result, the company is “evaluating potential cost-saving strategies,” CEO Scott Braunstein, M.D., said in a release.
MedCity News
APRIL 15, 2024
Current technology can’t single-handedly solve all dental workforce issues, but there is much it can do to lighten the burden. The post How Technology Can Alleviate Dental Workforce Challenges appeared first on MedCity News.
Fierce Pharma
APRIL 15, 2024
As Genentech bolsters its hematology portfolio with new antibody drugs and bispecifics, the Roche unit has revealed a trial win that could push its recently approved T-cell engager Columvi int | The study paired Columvi, a CD20xCD3 bispecific T-cell engager, with the chemotherapy GemOx (glofitamab-gxbm) in patients who’d tried at least one prior line of therapy and did not qualify for autologous stem cell transplants.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
APRIL 15, 2024
Positive data from MaaT Pharma’s Microbiome Ecosystem Therapy TM (MET) MaaT013 as a treatment for acute graft-versus-host disease (aGvHD), is set to be presented at the 2024 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting. Based on the long-term survival data, at 18 months MaaT013 enabled 42 percent overall survival in all patients and 58 percent in responder patients.
MedCity News
APRIL 15, 2024
The FDA clinical hold keeps Neumora Therapeutics from catching up to the field of biopharmaceutical companies pursuing the same target for schizophrenia. But Neumora remains on track with its lead program, a different drug in late-stage clinical testing for major depressive disorder. The post Preclinical Safety Signal Prompts FDA Clinical Hold on Neumora Schizophrenia Drug appeared first on MedCity News.
European Pharmaceutical Review
APRIL 15, 2024
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
pharmaphorum
APRIL 15, 2024
Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors to the board. In an open letter, the hedge fund accuses Novavax’s leadership of squandering its “many significant competitive advantages and sizeable market opportunity” due to “self-inflicted problems” under the current team led by chief executive John Jacobs.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
APRIL 15, 2024
Researchers investigating environmental microbial contamination found “no seasonal climatic influences were observed” in bacteria and fungi counts present in Grade D (ISO 8) Brazilian pharmaceutical cleanrooms. Samples were obtained via surface and air monitoring over a one-year period. While microbial levels were predicted to be higher during rainy periods compared to dry spells, “no statistically significant differences in bacteria and fungi counts were found between months or seasonal period
MedCity News
APRIL 15, 2024
Banner Health is deploying Qventus’ perioperative technology across the entire organization following the success of an initial pilot. The software integrates with EHRs and uses machine learning to automate operating room scheduling processes and maximize surgical caseloads. The post Why Banner Health Is Scaling Automation Tech In Its Operating Rooms appeared first on MedCity News.
pharmaphorum
APRIL 15, 2024
Life sciences service provider (and pharmaphorum parent company) Eversana has completed the integration of Healthware Group, the Italy-based global agency and consultancy it acquired in October. The group will now be known as Eversana Intouch Healthware and will operate as Eversana’s sixth full-service affiliate.
Pharmaceutical Commerce
APRIL 15, 2024
Results of the trial suggest that early intervention for intracerebral hemorrhage using parafascicular surgery were safe.
pharmaphorum
APRIL 15, 2024
Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings for earlier use of the drug in the treatment pathway.
PharmaTimes
APRIL 15, 2024
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
pharmaphorum
APRIL 15, 2024
Up to one in six people in eight industrialised nations could be suffering from chronic kidney disease (CKD) by 2032, with dire consequences for “patients, [the] planet, and economies,” says a new study.
PharmaTimes
APRIL 15, 2024
Approximately 14% of the competition-submitted proposals were selected to receive funding
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Clarivate
APRIL 15, 2024
Artificial intelligence (AI) is evolving rapidly with new business use cases constantly emerging. So, how do law firms and in-house counsels ensure they don’t get left behind? Our research found that IP professionals are currently grappling with what AI could mean for them, their practice and their processes. They are keen to realize benefits but are largely skeptical about AI deployment with relatively low industry adoption.
European Pharmaceutical Review
APRIL 15, 2024
Hot-melt extrusion can help overcome many pharmaceutical formulation challenges since it is a straightforward technique to compound all excipients on a molecular level. Various dosage forms can be produced with a twin-screw extruder and corresponding downstream equipment. These include solid oral dosage forms such as buccal and transdermal, as well as new delivery systems like subcutaneous implants and transmucosal applications.
Pharmaceutical Technology
APRIL 15, 2024
Discover ImmunityBio Inc's groundbreaking patent for a cross-reactive SARS-CoV2 vaccine targeting multiple variants. Learn how this innovative method boosts immune response and memory cells for enhanced protection.
Pharmaceutical Commerce
APRIL 15, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
APRIL 15, 2024
Discover Genzyme Corp's innovative method for detecting anti-drug antibodies in human body fluids. Learn how their patented process reduces interference in drug assays effectively.
PharmExec
APRIL 15, 2024
In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses why their drug isn't experiencing the same supply issues as the bigger names in the space.
Infuse Medical
APRIL 15, 2024
Sales enablement is a critical aspect of any business strategy aimed at driving revenue growth and fostering customer relationships. In today’s digital age, where consumers are bombarded with information from various channels, crafting engaging content plays a pivotal role in boosting sales performance. This comprehensive guide will delve into the intricacies of sales enablement and how businesses can leverage compelling content to drive conversions and achieve their sales objectives.
PharmExec
APRIL 15, 2024
Damien Bailly, president of established markets at Astellas, discusses why partnerships and collaborations are a critical organizational—and wider ecosystem—imperative in ensuring that patients have access to the medicines they need.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
268 
Let's personalize your content